Header Logo

NABIHAH TAYOB

TitleAssistant Professor
InstitutionMD Anderson
DepartmentBiostatistics
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Leone JP, Leone J, Hassett MJ, Freedman RA, Avila J, Vallejo CT, Tayob N, Tolaney SM, Lin NU. Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study. Breast Cancer Res Treat. 2024 Dec 02. PMID: 39621161.
      Citations:    Fields:    
    2. Raghavendra AS, Zakon DB, Jin Q, Strahan A, Grimm M, Hughes ME, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf EA, King TA, Valero V, Tripathy D, Tolaney SM, Tayob N, Lin NU, Stover DG, Barcenas CH, Garrido-Castro AC. Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status?. ESMO Open. 2024 Nov; 9(11):103973. PMID: 39500139; PMCID: PMC11570474.
      Citations:    Translation:Humans
    3. Singal AG, Parikh ND, Kanwal F, Marrero JA, Deodhar S, Page-Lester S, Lopez C, Feng Z, Tayob N. National Liver Cancer Screening Trial (TRACER) study protocol. Hepatol Commun. 2024 Nov 01; 8(11). PMID: 39495136; PMCID: PMC11537583.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, Leone JP, Mittendorf EA, Pereslete AM, Sharp L, Davis R, DiLullo M, Tayob N, Mayer EL, Winer EP, Tolaney SM, Lin NU, Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, Leone JP, Mittendorf EA, Pereslete AM, Sharp L, Davis R, DiLullo M, Tayob N, Mayer EL, Winer EP, Tolaney SM, Lin NU. A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4856-4865. PMID: 39226397; PMCID: PMC11528201.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Marsh TL, Parikh ND, Roberts LR, Schwartz ME, Nguyen MH, Befeler A, Page-Lester S, Tayob N, Srivastava S, Rinaudo JA, Singal AG, Reddy KR, Marrero JA, Marsh TL, Schwartz ME, Page-Lester S, Singal AG, Reddy KR, Marrero JA. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis. Gastroenterology. 2024 Sep 16. PMID: 39293548.
      Citations: 1     Fields:    
    6. Sandoval RL, Bottosso M, Tianyu L, Polidorio N, Bychkovsky BL, Verret B, Gennari A, Cahill S, Achatz MI, Caron O, Imbert-Bouteille M, Nogu?s C, Mawell KN, Fortuno C, Spurdle AB, Tayob N, Andre F, Garber JE, Sandoval RL, Bottosso M, Cahill S, Caron O, Fortuno C. TP53-associated early breast cancer: new observations from a large cohort. J Natl Cancer Inst. 2024 Aug 01; 116(8):1246-1254. PMID: 38569880; PMCID: PMC11308175.
      Citations: 1     Fields:    Translation:Humans
    7. Waks AG, Chen EL, Graham N, Frey AM, Almeida K, Attaya V, Ryding C, Abbass I, Fung A, Sussell J, Cortazar P, Harvey C, Leth D, Faggen M, Sinclair N, Walsh J, Tung N, Sinclair S, Lo S, Yardley D, Valero V, Meisel J, Ballinger TJ, Adams S, Carey LA, Rauch JK, Abramson VG, Williams NO, Chen WY, Leone JP, Schumer ST, Tayob N, Tolaney SM. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial). JCO Oncol Pract. 2024 Jul 19; OP2400021. PMID: 39028923.
      Citations:    Fields:    
    8. Freedman RA, Heiling HM, Li T, Trapani D, Tayob N, Smith KL, Davis R, Pereslete AM, DeMeo MK, Cotter C, Chen WY, Parsons HA, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Ashai N, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Rimawi MF, Krop IE, Lin NU, Freedman RA, Heiling HM, Li T, Trapani D, Tayob N, Smith KL, Davis R, Pereslete AM, DeMeo MK, Cotter C, Chen WY, Parsons HA, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Ashai N, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Rimawi MF, Krop IE, Lin NU. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024 Nov; 35(11):993-1002. PMID: 38977064.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    9. Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM, Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Nov; 42(31):3652-3665. PMID: 38935923; PMCID: PMC11527383.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    10. El-Serag HB, Jin Q, Nabihah T, Salem E, Luster M, Alsarraj A, Khaderi S, Singal AG, Marrero JA, Asrani SK, Kanwal F, El-Serag HB, Tayob N, Alsarraj A, Singal AG, Marrero JA, Asrani SK. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2024 Jun 19. PMID: 38899967.
      Citations: 1     Fields:    
    11. Grinshpun A, Ren S, Graham N, DeMeo MK, Wrabel E, Carter J, Tayob N, Pereslete A, Hamilton E, Juric D, Mayer EL, Tolaney SM, Krop IE, Metzger O. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer. ESMO Open. 2024 Jun; 9(6):103465. PMID: 38833970; PMCID: PMC11179085.
      Citations:    Translation:HumansCTClinical Trials
    12. Kipnis LM, Breen KM, Koeller DR, Levine AS, Yang Z, Jun H, Tayob N, Stokes SM, Hayes CP, Ghazani AA, Hill SJ, Rana HQ. Germline and Somatic Fumarate Hydratase Testing in Atypical Uterine Leiomyomata. Cancer Prev Res (Phila). 2024 May 02; 17(5):201-208. PMID: 38638033; PMCID: PMC11439430.
      Citations:    Fields:    Translation:Humans
    13. Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ Breast Cancer. 2024 Apr 16; 10(1):28. PMID: 38627457; PMCID: PMC11021554.
      Citations:    
    14. Chiang S, Grogan T, Kamounah S, Wei F, Tayob N, Kim JY, Kyun Park J, Akin D, Elashoff DA, Pedersen AML, Song YW, Wong DTW, Chia D. Distinctive profile of monomeric and polymeric anti-SSA/Ro52 immunoglobulin A1 isoforms in saliva of patients with primary Sj?gren's syndrome and Sicca. RMD Open. 2024 04 10; 10(2). PMID: 38599651; PMCID: PMC11015269.
      Citations:    Translation:Humans
    15. Tarantino P, Leone J, Vallejo CT, Freedman RA, Waks AG, Mart?nez-S?ez O, Garrido-Castro A, Lynce F, Tayob N, Lin NU, Tolaney SM, Leone JP. Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ Breast Cancer. 2024 Apr 04; 10(1):26. PMID: 38575691; PMCID: PMC10995121.
      Citations: 2     
    16. Daher D, Seif El Dahan K, Rich NE, Tayob N, Merrill V, Huang DQ, Yang JD, Kulkarni AV, Kanwal F, Marrero J, Parikh N, Singal AG. Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients. JAMA Netw Open. 2024 Apr 01; 7(4):e248755. PMID: 38683607; PMCID: PMC11059036.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    17. Leone J, Hassett MJ, Freedman RA, Tolaney SM, Graham N, Tayob N, Vallejo CT, Winer EP, Lin NU, Leone JP. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Apr 01; 10(4):508-515. PMID: 38421673; PMCID: PMC10905378.
      Citations: 2     Fields:    Translation:Humans
    18. G?mez Tejeda Za?udo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, Pereslete A, Abravanel DL, Ferreira AR, Wrabel E, Helvie K, Hughes ME, Partridge AH, Overmoyer B, Lin NU, Tayob N, Tolaney SM, Wagle N. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446. PMID: 38503755; PMCID: PMC10951222.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    19. Tarantino P, Ajari O, Graham N, Vincuilla J, Parker T, Hughes ME, Tayob N, Garrido-Castro AC, Morganti S, King TA, Mittendorf EA, Curigliano G, Lin NU, Tolaney SM. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer. 2024 Apr; 201:113920. PMID: 38368741.
      Citations: 3     Fields:    Translation:Humans
    20. Morganti S, Gibson CJ, Jin Q, Santos K, Patel A, Wilson A, Merrill M, Vincuilla J, Stokes S, Lipsyc-Sharf M, Parker T, King TA, Mittendorf EA, Curigliano G, Hughes ME, Stover DG, Tolaney SM, Weeks LD, Tayob N, Lin NU, Garber JE, Miller PG, Parsons HA. Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. J Clin Oncol. 2024 Nov; 42(31):3666-3679. PMID: 38190580.
      Citations: 1     Fields:    Translation:Humans
    21. Guerriero JL, Lin JR, Pastorello RG, Du Z, Chen YA, Townsend MG, Shimada K, Hughes ME, Ren S, Tayob N, Zheng K, Mei S, Patterson A, Taneja KL, Metzger O, Tolaney SM, Lin NU, Dillon DA, Schnitt SJ, Sorger PK, Mittendorf EA, Santagata S. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024 Jan 02; 10(1):2. PMID: 38167908; PMCID: PMC10761880.
      Citations: 1     
    22. Weiss A, Jin Q, Waks AG, Yardley D, Spring LM, Wrabel E, Tayob N, Viale G, Krop IE, King TA, Metzger-Filho O. Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. J Am Coll Surg. 2024 Mar 01; 238(3):303-311. PMID: 38047578.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    23. Mayer EL, Tayob N, Ren S, Savoie JJ, Spigel DR, Burris HA, Ryan PD, Harris LN, Winer EP, Burstein HJ. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Feb; 204(1):123-132. PMID: 38019444.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    24. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garc?a-Pedrero J, Ca?adas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 10 02; 83(19):3284-3304. PMID: 37450351; PMCID: PMC10543960.
      Citations:    Fields:    Translation:HumansCells
    25. Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906. PMID: 37597579; PMCID: PMC10898256.
      Citations: 3     Fields:    Translation:Humans
    26. Mayerhofer C, Sedrak MS, Hopkins JO, Li T, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Wong AR, Tiwari A, McAllister SS, Mittendorf EA, Gibson CJ, Burstein HJ, Kim AS, Freedman RA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Miller PG. Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy. J Natl Cancer Inst. 2023 08 08; 115(8):981-988. PMID: 37042724; PMCID: PMC10407695.
      Citations: 1     Fields:    Translation:Humans
    27. Kamounah S, Tayob N, Chiang S, Wei F, Park JK, Kwon HM, Feng Z, Chia D, Pedersen AML, Song YW, Wong DTW. Immunoassay Detects Salivary Anti-SSA/Ro-52 Autoantibodies in Seronegative Patients with Primary Sj?gren's Syndrome. Immunohorizons. 2023 07 01; 7(7):554-561. PMID: 37466644; PMCID: PMC10587502.
      Citations:    Fields:    Translation:Humans
    28. Leone JP, Graham N, Leone J, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Vallejo CT, Winer EP, Lin NU, Tayob N. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool. Eur J Cancer. 2023 08; 189:112930. PMID: 37356327.
      Citations:    Fields:    Translation:Humans
    29. Weiss A, Li T, Desai NV, Tung NM, Poorvu PD, Partridge AH, Nakhlis F, Dominici L, Sinclair N, Spring LM, Faggen M, Constantine M, Krop IE, DeMeo M, Wrabel E, Alberti J, Chikarmane S, Tayob N, King TA, Tolaney SM, Winer EP, Mittendorf EA, Waks AG. Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. J Am Coll Surg. 2023 08 01; 237(2):247-256. PMID: 37194964.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    30. Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJ. Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncol Pract. 2023 08; 19(8):560-570. PMID: 37192427.
      Citations:    Fields:    Translation:Humans
    31. Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. medRxiv. 2023 Mar 08. PMID: 36945501; PMCID: PMC10029037.
      Citations:    
    32. Tolaney SM, Tarantino P, Graham N, Tayob N, Par? L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 03; 24(3):273-285. PMID: 36858723.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    33. Tarantino P, Tayob N, Tolaney SM. Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply. JAMA Oncol. 2023 01 01; 9(1):147-148. PMID: 36327124.
      Citations: 1     Fields:    Translation:Humans
    34. Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Getz G, Jeselsohn R. Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2022 12 01; 28(23):5066-5078. PMID: 36215125; PMCID: PMC9722539.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    35. Sella T, Zheng Y, Tayob N, Ruddy KJ, Freedman RA, Dang C, Yardley D, Isakoff SJ, Valero V, DeMeo M, Burstein HJ, Winer EP, Wolff AC, Krop I, Partridge AH, Tolaney SM. Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). NPJ Breast Cancer. 2022 Nov 30; 8(1):127. PMID: 36450763; PMCID: PMC9712612.
      Citations: 2     
    36. Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, L?nning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clin Cancer Res. 2022 11 01; 28(21):4714-4723. PMID: 36048535; PMCID: PMC9623231.
      Citations:    
    37. Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022 10; 10(10). PMID: 36252998; PMCID: PMC9577940.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    38. Freedman RA, Li T, Sedrak MS, Hopkins JO, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong A, Tiwari A, McAllister SS, Mittendorf EA, Miller PG, Gibson CJ, Burstein HJ. 'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer. J Geriatr Oncol. 2023 Jan; 14(1):101377. PMID: 36163163; PMCID: PMC10080267.
      Citations: 1     Fields:    Translation:Humans
    39. Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatol. 2023 01; 78(1):207-216. PMID: 36089157; PMCID: PMC10229257.
      Citations:    
    40. Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322. PMID: 35900726; PMCID: PMC9335244.
      Citations:    Fields:    
    41. Choi J, Tayob N, Lim YS. Detecting Early Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Using Longitudinal a-Fetoprotein Screening. Clin Gastroenterol Hepatol. 2023 06; 21(6):1590-1597. PMID: 36031091; PMCID: PMC9968818.
      Citations:    
    42. Liu M, Tayob N, Penter L, Sellars M, Tarren A, Chea V, Carulli I, Huang T, Li S, Cheng SC, Le P, Frackiewicz L, Fasse J, Qi C, Liu JF, Stover EH, Curtis J, Livak KJ, Neuberg D, Zhang G, Matulonis UA, Wu CJ, Keskin DB, Konstantinopoulos PA. Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clin Cancer Res. 2022 08 02; 28(15):3356-3366. PMID: 35443043; PMCID: PMC9357177.
      Citations:    Fields:    
    43. Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022 08 01; 8(8):1177-1183. PMID: 35737367; PMCID: PMC9227690.
      Citations: 1     Fields:    
    44. Graham N, Tolaney SM, Freedman RA, Hassett MJ, Winer EP, Lin NU, Tayob N, Leone JP, Leone BA, Leone J, Vallejo CT. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. Eur J Cancer. 2022 09; 173:20-29. PMID: 35841843.
      Citations:    Fields:    
    45. Parikh ND, Tayob N, Al-Jarrah T, Kramer J, Melcher J, Smith D, Marquardt P, Liu PH, Tang R, Kanwal F, Singal AG. Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort. JAMA Netw Open. 2022 07 01; 5(7):e2223504. PMID: 35867057; PMCID: PMC9308050.
      Citations:    Fields:    Translation:Humans
    46. Sella T, Zheng Y, Tan-Wasielewski Z, Rosenberg SM, Poorvu PD, Tayob N, Ruddy KJ, Gelber SI, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Partridge AH, Ligibel JA. Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors. Cancer. 2022 09 01; 128(17):3158-3169. PMID: 35775874.
      Citations:    Fields:    
    47. Sella T, Ren S, Freret TS, Economy KE, Chen WY, Parsons HA, Lin NU, Moy B, Tung NM, Partridge AH, Tayob N, Mayer EL, Exman P. Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis. Breast Cancer Res Treat. 2022 Aug; 194(3):597-606. PMID: 35715538.
      Citations:    Fields:    Translation:Humans
    48. Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, Kim JS, Umeton R, Awad MM, Konstantinopoulos PA, Yurgelun MB, Wolpin BM, Taplin ME, Newmark RE, Johnson BE, Lindeman NI, MacConaill LE, Garber JE, Lin NU. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022 06 01; 28(11):2349-2360. PMID: 35363308; PMCID: PMC9167798.
      Citations:    Fields:    Translation:Humans
    49. Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer. 2022 May 10; 8(1):63. PMID: 35538105; PMCID: PMC9091255.
      Citations:    
    50. Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, Swisher EM, Matulonis UA, Wulf GM, Mayer EL. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 04 14; 28(8):1493-1499. PMID: 35149538; PMCID: PMC9066379.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    51. Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974. PMID: 35434236; PMCID: PMC9011027.
      Citations:    
    52. Benhammou JN, Rich NE, Cholankeril G, Zhang P, Zeng W, Rao S, Tayob N, National Cancer Institute?s Translational Liver Consortium Early-Career Working Group. DETECT: Development of Technologies for Early HCC Detection. Gastroenterology. 2022 07; 163(1):21-27. PMID: 35339460; PMCID: PMC9232964.
      Citations:    Fields:    Translation:Humans
    53. Tayob N, Lok ASF, Feng Z. A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Stat Med. 2022 06 15; 41(13):2338-2353. PMID: 35199349; PMCID: PMC9035119.
      Citations:    Fields:    Translation:Humans
    54. Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM, Barroso-Sousa R. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18. PMID: 35173164; PMCID: PMC8850608.
      Citations:    
    55. Tayob N, Kanwal F, Alsarraj A, Hernaez R, El-Serag HB. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4. PMID: 35124267; PMCID: PMC9346092.
      Citations: 1     Fields:    
    56. Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Lederman RI, Frank E, Sohl JJ, Stadler ZK, Erick TK, Peppercorn J, Winer EP, Silverman SG, Come SE, Lin NU. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Res Treat. 2022 Feb; 192(1):201-210. PMID: 35066788.
      Citations:    Fields:    Translation:Humans
    57. Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SM. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):117-124. PMID: 34990776.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    58. Tayob N, Feng Z. Personalized statistical learning algorithms to improve the early detection of cancer using longitudinal biomarkers. Cancer Biomark. 2022; 33(2):199-210. PMID: 35213362; PMCID: PMC9020369.
      Citations:    Fields:    Translation:Humans
    59. Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022 03; 75(3):541-549. PMID: 34618932; PMCID: PMC8844059.
      Citations: 6     Fields:    Translation:Humans
    60. Tolaney SM, Lydon CA, Li T, Dai J, Standring A, Legor KA, Caparrotta CM, Schenker MP, Glazer DI, Tayob N, DuBois SG, Meyerhardt JA, Taplin ME, Johnson BE. The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2021 11 02; 113(11):1453-1459. PMID: 32959883; PMCID: PMC7543498.
      Citations: 17     Fields:    Translation:HumansCells
    61. Parsons HA, Macrae ER, Guo H, Li T, Barry WT, Tayob N, Wulf GM, Isakoff SJ, Krop IE. Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precis Oncol. 2021 11; 5:896-903. PMID: 34994617; PMCID: PMC9848583.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    62. Pudakalakatti S, Audia A, Mukhopadhyay A, Enriquez JS, Bourgeois D, Tayob N, Zacharias NM, Millward SW, Carson D, Farach-Carson MC, Lang FF, Heimberger AB, Bhat KP, Bhattacharya PK. NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors. Reports (MDPI). 2021 Dec; 4(4). PMID: 35937580; PMCID: PMC9352435.
      Citations:    
    63. Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NU. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933. PMID: 34472667; PMCID: PMC8571744.
      Citations:    Fields:    Translation:Humans
    64. Konstantinopoulos PA, Gulhan D, Lee EK, Cheng SC, Hendrickson AEW, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Stover EH, Curtis J, Tayob N, Polak M, Chowdhury D, Matulonis UA, D'Andrea AD, Shapiro GI, da Costa AABA, F?rkkil? A. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574. PMID: 34552099; PMCID: PMC8458434.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    65. Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563. PMID: 34548479; PMCID: PMC8455578.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    66. Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110. PMID: 34433812; PMCID: PMC8387440.
      Citations: 1     
    67. Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, Abraham E, Juric D, Isakoff SJ, Mayer E, Moy B, Supko JG, Tolaney SM, Bardia A. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Aug 04; 7(1):103. PMID: 34349115; PMCID: PMC8339067.
      Citations: 2     
    68. Hassett MJ, Graham N, Tayob N, Freedman RA, Tolaney SM, Winer EP, Lin NU, Leone JP, Vallejo CT, Leone J, Leone BA. Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305. PMID: 34231078; PMCID: PMC8302547.
      Citations: 1     Fields:    
    69. Balch SM, Vaz-Luis I, Li T, Tayob N, Jain E, Helvie K, Buendia-Buendia JE, Shannon E, Isakoff SJ, Tung NM, Krop IE, Lin NU, Wagle N, Freedman RA. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Res Treat. 2021 Sep; 189(2):411-423. PMID: 34302589.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    70. Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110. PMID: 34120223.
      Citations: 4     Fields:    Translation:Humans
    71. Occhiogrosso RH, Ren S, Tayob N, Li T, Gagnon HC, Paz A, Freedman RA. Feasibility of an Online Patient Community to Support Older Women With Newly Diagnosed Breast Cancer. Clin Breast Cancer. 2022 02; 22(2):178-185. PMID: 34275766.
      Citations:    Fields:    Translation:Humans
    72. Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385. PMID: 34077270.
      Citations: 14     Fields:    Translation:Humans
    73. Hassett MJ, Graham N, Tayob N, Freedman RA, Tolaney SM, Winer EP, Lin NU, Leone JP, Vallejo CT, Leone J, Leone BA. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212. PMID: 33893907; PMCID: PMC8302525.
      Citations: 1     Fields:    Translation:Humans
    74. Singal AG, Tayob N, Mehta A, Marrero JA, Jin Q, Lau J, Parikh ND. Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2022 04; 20(4):953-955.e2. PMID: 33864933; PMCID: PMC8526617.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    75. Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539. PMID: 33705205.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    76. Singal AG, Hoshida Y, Pinato DJ, Marrero J, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Villanueva A, Nault JC, Llovet JM. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology. 2021 06; 160(7):2572-2584. PMID: 33705745; PMCID: PMC8169638.
      Citations: 19     Fields:    Translation:Humans
    77. Schrier E, Xiong N, Thompson E, Poort H, Schumer S, Liu JF, Krasner C, Campos SM, Horowitz NS, Feltmate C, Konstantinopoulos PA, Dinardo MM, Tayob N, Matulonis UA, Patel M, Wright AA. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586. PMID: 33637350.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    78. Tayob N, Hassett MJ, Freedman RA, Tolaney SM, Winer EP, Lin NU, Leone JP, Leone BA, Leone J, Vallejo CT. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852. PMID: 33590387.
      Citations: 2     Fields:    Translation:Humans
    79. Seah DS, Leone JP, Openshaw TH, Scott SM, Tayob N, Hu J, Lederman RI, Frank ES, Sohl JJ, Stadler ZK, Erick TK, Silverman SG, Peppercorn JM, Winer EP, Come SE, Lin NU. Perceptions of patients with early stage breast cancer toward research biopsies. Cancer. 2021 04 15; 127(8):1208-1219. PMID: 33320362; PMCID: PMC8247276.
      Citations: 3     Fields:    Translation:Humans
    80. Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):983-991. PMID: 33257427; PMCID: PMC7887044.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    81. Tayob N, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, White DL, Davila J, Kanwal F, El-Serag HB. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2021 07; 19(7):1443-1450.e6. PMID: 32768590; PMCID: PMC8201947.
      Citations: 7     Fields:    Translation:Humans
    82. Xia M, Murray S, Tayob N. Nonparametric group sequential methods for recurrent and terminal events from multiple follow-up windows. Stat Med. 2019 12 30; 38(30):5657-5669. PMID: 31732980.
      Citations: 1     Fields:    Translation:Humans
    83. Xia M, Murray S, Tayob N. Regression analysis of recurrent-event-free time from multiple follow-up windows. Stat Med. 2020 01 15; 39(1):1-15. PMID: 31663647.
      Citations:    Fields:    Translation:Humans
    84. Nelson DB, Tayob N, Nguyen QN, Erasmus J, Mitchell KG, Hofstetter WL, Sepesi B, Antonoff MB, Mehran RJ. Local failure after stereotactic body radiation therapy or wedge resection for colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019 10; 158(4):1234-1241.e16. PMID: 31395367.
      Citations: 1     Fields:    Translation:Humans
    85. Xia M, Murray S, Tayob N. Nonparametric group sequential methods for evaluating survival benefit from multiple short-term follow-up windows. Biometrics. 2019 06; 75(2):494-505. PMID: 30456786.
      Citations:    Fields:    Translation:Humans
    86. Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5. PMID: 30557738; PMCID: PMC6570589.
      Citations: 16     Fields:    Translation:Humans
    87. Nelson DB, Tayob N, Mitchell KG, Correa AM, Hofstetter WL, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff MB, Roth JA, Rice DC, Vauthey JN, Mehran RJ. Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019 04; 157(4):1648-1655. PMID: 30635188.
      Citations: 5     Fields:    Translation:Humans
    88. Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, Criner G, Galban CJ, Ross BD, Hoffman EA, Lynch DA, Kazerooni E, Martinez FJ, COPDGene and SPIROMICS Investigators. Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials. Am J Respir Crit Care Med. 2018 07 15; 198(2):265-267. PMID: 29485901; PMCID: PMC6058986.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    89. Tayob N, Richardson P, White DL, Yu X, Davila JA, Kanwal F, Feng Z, El-Serag HB. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1. PMID: 29301497; PMCID: PMC5753461.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    90. Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, Kazerooni EA, Sundaram B, Chughtai AR, Martinez FJ, Flaherty KR. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med. 2017 10; 131:229-235. PMID: 28947036; PMCID: PMC5679475.
      Citations: 10     Fields:    Translation:Humans
    91. Tayob N, Stingo F, Do KA, Lok ASF, Feng Z. A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics. 2018 03; 74(1):249-259. PMID: 28482112; PMCID: PMC5677596.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    92. Tayob N, Murray S. Statistical consequences of a successful lung allocation system - recovering information and reducing bias in models for urgency. Stat Med. 2017 07 10; 36(15):2435-2451. PMID: 28324918.
      Citations: 2     Fields:    Translation:Humans
    93. Tayob N, Do KA, Feng Z. Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design. Biometrics. 2016 09; 72(3):888-96. PMID: 26845527; PMCID: PMC4974170.
      Citations: 3     Fields:    Translation:Humans
    94. Tayob N, Murray S. Nonparametric restricted mean analysis across multiple follow-up intervals. Stat Probab Lett. 2016 Feb 01; 109:152-158. PMID: 26858468; PMCID: PMC4743536.
      Citations:    
    95. Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, Wells AU, Schmidt SL, Martinez FJ, Flaherty KR. Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest. 2016 Feb; 149(2):491-498. PMID: 26425858; PMCID: PMC4944785.
      Citations: 23     Fields:    
    96. Tayob N, Lok AS, Do KA, Feng Z. Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):469-475.e2. PMID: 26260109; PMCID: PMC4744807.
      Citations: 34     Fields:    Translation:HumansPHPublic Health
    97. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, Albert R, Woodruff P, Martinez FJ. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014 Jun 15; 189(12):1503-8. PMID: 24779680; PMCID: PMC4226018.
      Citations: 45     Fields:    Translation:Humans
    98. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, Martinez FJ, COMET Investigators. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014 Jul; 2(7):548-56. PMID: 24767767; PMCID: PMC4142525.
      Citations: 150     Fields:    Translation:HumansCellsCTClinical Trials
    99. Tayob N, Murray S. Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events. Biostatistics. 2015 Jan; 16(1):73-83. PMID: 24719282; PMCID: PMC4263220.
      Citations:    Fields:    Translation:Humans
    100. Schmidt SL, Tayob N, Han MK, Zappala C, Kervitsky D, Murray S, Wells AU, Brown KK, Martinez FJ, Flaherty KR. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest. 2014 Mar 01; 145(3):579-585. PMID: 24231810; PMCID: PMC3941249.
      Citations: 31     Fields:    Translation:Humans
    101. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, Fry CD, White ES, Sisson TH, Tayob N, Carnemolla B, Orecchia P, Flaherty KR, Hershenson MB, Murray S, Martinez FJ, Moore BB, COMET Investigators. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15; 303(12):L1046-56. PMID: 23043074; PMCID: PMC3532583.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    102. Moodley P, Shah NS, Tayob N, Connolly C, Zetola N, Gandhi N, Friedland G, Sturm AW. Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. PLoS One. 2011; 6(5):e17513. PMID: 21655324; PMCID: PMC3104985.
      Citations: 20     Fields:    Translation:Humans
    103. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J. 2011 Jul; 38(1):176-83. PMID: 21148225; PMCID: PMC4084829.
      Citations: 45     Fields:    Translation:HumansCells
    104. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 Oct 28; 302(16):1790-5. PMID: 19861671; PMCID: PMC4091624.
      Citations: 194     Fields:    Translation:HumansCells
    105. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009 Nov; 137(5):1621-7. PMID: 19622357; PMCID: PMC2767441.
      Citations: 141     Fields:    Translation:HumansCells
    106. Nonparametric restricted mean analysis across multiple follow-up intervals. Statistics and Probability Letters. 109:152-158.
    107. Idiopathic pulmonary fibrosis. Chest. 149:491-498.
    108. Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clinical Gastroenterology and Hepatology. 14:469-475.e2.
    TAYOB's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (318)
    Explore
    _
    Co-Authors (41)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _